ASCO – Page 4 – malecare.org

From the 2013 Genitourinary Cancers Symposium – An Update of the Abiraterone Acetate (Zytiga) with Prednisone Clinical Trial

At the recent 2013 2013 Genitourinary Cancers Symposium there was an abstract presented that updated data from the COU-AA-302 clinical trial of Abiraterone Acetate (Zytiga) with prednisone. The updated data confirms that Zytiga with prednisone improves overall survival (OS) in men with metastatic castrate resistant prostate cancer (mCRPC) post-docetaxel therapy (chemotherapy)(Lancet Oncol 2012;13:983-92). The trial [...]

By Malecare|2017-10-19T10:50:08-04:00February 25th, 2013|abiraterone acetate, Advanced Prostate Cancer, ASCO, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Zytiga|0 Comments

From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade

Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not know what is the optimal duration of AB. Looking at this problem, the researchers conducted a randomized study to compare [...]

By Malecare|2013-02-17T10:43:04-05:00February 17th, 2013|adjuvant therapy, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Radiotherapy, Uncategorized|0 Comments

Two More Provenge Related Abstracts from the 2013 ASCO GU Symposium

More on Sipuleucel-T (Provenge) from the 2013 The last two abstracts that I want to speak about that were presented at the conference that pertained to Provenge speak to its efficacy. The first looks at changes in circulating tumor cells (CTC) and the second to the onset of the use of opioid painkillers. Abstract #40 [...]

By Malecare|2017-10-19T10:50:08-04:00February 15th, 2013|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, inflammation, Pain, Provenge, Research, Uncategorized, Understanding APC|0 Comments

From the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium – News of Provenge

Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I [...]

By Malecare|2020-02-04T08:56:36-05:00February 14th, 2013|abiraterone acetate, Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Combination Therapy, Drugs & Treatments, Hormone Therapy, Research, Uncategorized|0 Comments

Coming in Early 2013 – A Genetic Test to Predict Which Prostate Cancers Need treatment and Which can be Subject to Active Surveillance

Genomic Health, Inc. has announced they have had positive results from a large clinical validation study of a biopsy-based prostate cancer test designed to predict adverse pathology in men with early prostate cancer. The study, performed in collaboration with prostate cancer researchers at the University of California, San Francisco (UCSF), met its primary endpoint by [...]

By Malecare|2017-10-19T10:50:45-04:00September 22nd, 2012|Advanced Prostate Cancer, ASCO, biomarkers, Drugs & Treatments, General Information, genetics, Prostate Ponderings, Uncategorized, Understanding APC|1 Comment

Adding Radiotherapy to ADT Increases Survival for a Man Diagnosed with Locally Advanced Prostate Cancer

Men with locally advanced prostate cancer have a better survival chance if they receive radiotherapy along with androgen deprivation therapy (ADT). This data was presented at the recent American Society of Clinical Oncology (ASCO) 2012 conference. Professor Malcom Mason from Whales University discussed a trial he conducted that demonstrated that for a man diagnosed with [...]

By Malecare|2020-02-04T09:50:33-05:00August 10th, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, General Information, Hormone Therapy, Radiotherapy, Uncategorized, Understanding APC|0 Comments

Alpharadin Data Updated for the Treatment of Men with Advanced Prostate Cancer that has Spread to Bone

Algeta announced that updated data from the phase III trial, ALSYMPCA, for its investigational drug Alpharadin (radium-223 dichloride). The data confirmed the overall survival of men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases using Alpharadin, compared to the interim analysis from June 2011. • Overall survival in Alpharadin arm increased by 44% • [...]

By Malecare|2017-10-19T10:51:03-04:00June 15th, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, On The Horizon, Uncategorized|2 Comments

Dr. S. Meyers Posts a Video About Intermittent vs. Continuous Hormone Therapy for Men with Prostate Cancer and Bone Metastasis

On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy for men with advanced prostate cancer with bone metastasis is not [...]

By Malecare|2020-02-04T10:37:34-05:00June 13th, 2012|Advanced Prostate Cancer, ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Metastases, Uncategorized, Understanding APC|0 Comments

From ASCO: Liver Metastases And Its Prognostic Significance In Men With Metastatic Prostate Cancer

According to data presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655) the presences of liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC). William Kevin Kelly, DO, Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson, and colleagues from the [...]

By Malecare|2017-10-19T10:51:06-04:00June 11th, 2012|Advanced Prostate Cancer, ASCO, biomarkers, Clinical Trials, Clinical Trials, General Information, Metastases, Uncategorized, Understanding APC|0 Comments

My Current Personal Take on Intermittent Hormone Therapy for Prostate Cancer

On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy is not as good as continuous hormone therapy with regard to [...]

By Malecare|2017-10-19T10:51:06-04:00June 7th, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Me, Uncategorized, Understanding APC|8 Comments